Compare Abeona Therapeutics Inc (ABEO) vs Expensify Inc (EXFY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Expensify Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Expensify Inc trades at $1.88 (market cap $179.86M). The key difference: Abeona Therapeutics Inc is far larger — about 2.1× Expensify Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Expensify Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | EXFY | |
|---|---|---|
Market Cap | $373.32M | $179.86M |
Sector | Health | Technology |
52-Week High | $7.23 | $2.51 |
52-Week Low | $4.17 | $0.75 |
Enterprise Value | $228.22M | $118.89M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Expensify (EXFY) trades at $1.71, up 0.59% with a bullish technical signal from moving averages. The company maintains strong revenue around $142M but continues to report net losses, with a negative net income margin of -14.68%. Recent developments include AI product expansions and a $25M stock buyback program. Analyst sentiment is mixed with a 44% buy rating, while technical indicators show RSI levels suggesting potential overbought conditions near-term.
The outlook remains challenging with persistent profitability issues despite stable revenue. Investment opportunity exists in the company's AI initiatives and market positioning, but risks include ongoing losses, competitive pressure, and execution challenges. The stock's high P/E ratio of 258.82 reflects growth expectations that must materialize to justify current valuation levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
